
<DOC>
<DOCNO>
WSJ900504-0062
</DOCNO>
<DOCID>
900504-0062.
</DOCID>
<HL>
   Genzyme Unit's Initial Offering
</HL>
<DATE>
05/04/90
</DATE>
<SO>
WALL STREET JOURNAL (J), PAGE C9
</SO>
<CO>
   IGLI GENZ
</CO>
<IN>
STOCK MARKET, OFFERINGS (STK)
INITIAL STOCK OFFERINGS (INI)
</IN>
<LP>
   FRAMINGHAM, Mass. -- IG Laboratories Inc., a unit of
Genzyme Corp., said it is offering 1,875,000 common shares in
its initial public offering at $7.50 a share. All of the
shares are being offered by the company.
   Upon completion of the offering, IG Laboratories will have
about 5.1 million shares outstanding and will be 56% owned by
Genzyme, a Boston-based maker of health-care products. IG
Labs provides genetic testing services to hospitals and other
health-care providers.
</LP>
<TEXT>
   Oppenheimer &amp; Co. is the managing underwriter of the
offering.
</TEXT>
</DOC>